A Single-Center, Randomized, Double-masked, Vehicle-controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model
Latest Information Update: 19 Nov 2024
Price :
$35 *
At a glance
- Drugs TL-925 (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Telios Pharmaceuticals
- 19 Nov 2024 New trial record